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A B S T R A C T
HIV-exposed uninfected (HEU) children may have altered immune regulation and poorer neurodevelopment
outcomes compared to their HIV-unexposed (HU) counterparts. However, studies investigating the association of
maternal and infant inflammation with neurodevelopment in HEU children are limited and longitudinal data are
lacking. This study investigated serum inflammatory markers in women living with HIV vs. HIV-uninfected
women during pregnancy and in their children, as well as associations with neurodevelopmental outcomes at
two years of age in an African birth cohort study. A sub-group of mother–child dyads from the Drakenstein Child
Health Study had serum inflammatory markers measured at ≈26week’s gestation (n= 77 HIV-infected mo-
thers; n= 190 HIV-uninfected mothers), at 6–10weeks (n= 63 HEU infants and n= 159 HU infants) and at
24–28months (n= 77 HEU children and n= 190 HU children). Serum inflammatory markers [granulocyte–-
macrophage colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ), interleukin IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-10, IL-12p70, IL-13, tumor necrosis factor-α (TNF-α), neutrophil gelatinase-associated lipocalin
(NGAL) and metalloproteinase-9 (MMP-9)] were analyzed with a multiplex bead array and ELISA assays. The
Bayley Scales of Infant and Toddler Development, third edition, was used to assess neurodevelopment at
24–28months. After correcting for multiple comparisons, HIV infection during pregnancy was associated with
lower serum levels of inflammatory markers in mothers at 26weeks gestation (GM-CSF and MMP-9, p < 0.05)
and HEU children at 6–10weeks (IFN-γ and IL-1β, p < 0.01), and at 24–28months (IFN-γ, IL-1β, IL-2 and IL-4,
p < 0.05) compared to HIV-uninfected mothers and HU children. In HEU infants at 6–10weeks, inflammatory
markers (GM-CSF, IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-6 and NGAL, all p < 0.05) were associated with
poorer motor function at two years of age. This is the first study to evaluate the associations of follow-up immune
markers in HEU children with neurodevelopment. These findings suggest that maternal HIV infection is asso-
ciated with immune dysregulation in mothers and their children through two years of age. An altered immune
system in HEU infants is associated with poorer follow-up motor neurodevelopment. These data highlight the
important role of the immune system in early neurodevelopment and provide a foundation for future research.
1. Introduction
Maternal Human Immunodeficiency Virus (HIV) infection affects
maternal physiology and may have far-reaching consequences for the
development of the exposed fetus and child. With wider access to an-
tiretroviral therapy (ART) to prevent transmission of HIV from mother
to child, the number of HIV-exposed uninfected (HEU) children is in-
creasing. This is particularly relevant in South Africa, where the mo-
ther-to-child transmission rate dropped to < 5% in 2018, resulting in a
current HEU child population of 3 500 000 (UNAIDS, 2019). However,
HEU children are at increased risk of morbidity and mortality (Ajibola
et al., 2018; Brennan et al., 2016; Evans et al., 2016), and impaired
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neurodevelopment (McHenry et al., 2018; Wedderburn et al., 2019b).
Several mechanisms have been proposed to explain the adverse
outcomes in HEU children including; maternal and child immune dys-
regulation, ART toxicity, higher exposure to infectious diseases and
socio-environmental factors (Wedderburn et al., 2019a). The impact of
HIV infection on the adaptive immune system has been well described
in adults (Mohan et al., 2014). However, few studies have examined
maternal immunity in pregnancy in the context of HIV infection. Pre-
vious reports suggest that HIV impacts the maternal immune system by
creating a pro-inflammatory environment, which is characterized pre-
dominantly by increased levels of certain cytokines, such as interleukin
(IL-1, IL-6) and tumor necrosis factor-α (TNF-α) (Faye et al., 2007;
Richardson and Weinberg, 2011; Sachdeva et al., 2008). Findings from
studies have shown suppression of cytokine levels in pregnant women
living with HIV (Maharaj et al., 2017; Moussa et al., 2001). Further,
altered immune regulation may be present in HEU children (Abu-Raya
et al., 2016a). The vulnerability of the immune system in HEU children
is also suggested by the increase in morbidity and mortality in HEU
infants (Afran et al., 2014). However, results on HEU children in-
flammatory profiles are inconsistent, with evidence for both increased
levels (Dirajlal-Fargo et al., 2019; Miyamoto et al., 2017; Prendergast
et al., 2017) as well as reduced levels of cytokines in HEU children
(Borges-Almeida et al., 2011; Chougnet et al., 2000).
A recent meta-analysis found poorer cognitive and motor neurode-
velopment in HEU children (McHenry et al., 2018). Additionally, we
have found adverse language outcomes at 2 years in HEU infants in the
Drakenstein Child Health Study (DCHS) in South Africa (Wedderburn
et al., 2019b). Another study in Botswana showed that HEU children
performed similarly on neurodevelopmental assessments at 2 years of
age compared to HU children, although HEU children had increased
adverse expressive language outcomes (Chaudhury et al., 2017). The
biological mechanisms underlying neurodevelopmental impairments in
HEU children remain largely unknown. Studies suggest that maternal
immune activation and increased levels of certain inflammatory mar-
kers during pregnancy may contribute to poor fetal brain development
(Bilbo and Schwarz, 2012; Hsiao and Patterson, 2012; Morelli et al.,
2015; White et al., 2020). Due to the expanding population of HEU
children and concerns about neurodevelopmental vulnerability in these
children, the association between HIV, the immune system and neu-
rodevelopment is a critical area of investigation.
Based on existing literature showing that inflammatory markers are
increased in people living with HIV, we first hypothesized that pregnant
women living with HIV would have an increased pro-inflammatory
profile compared to HIV-uninfected pregnant women. Secondly, pre-
vious studies have found an association between increased levels of
inflammatory markers with neurodevelopmental disorders, therefore
we hypothesized that there would be an association between increased
levels of inflammatory markers with poorer neurodevelopmental out-
comes in children at 2 years of age.
The aims of this study were to investigate the impact of HIV on
inflammatory profiles of pregnant women and their uninfected children
through two years, and to assess whether these are associated with




A sub-sample of randomly selected mother–child pairs (n=267)
from the Drakenstein Child Health Study (DCHS), a large population-
based birth cohort, as previously described, were included in this study
(Stein et al., 2015; Zar et al., 2015). In brief, enrolment took place
between 2012 and 2015 at two primary health care clinics, TC Newman
and Mbekweni in Paarl, South Africa. All births occurred at Paarl
Hospital. Pregnant women were enrolled if they were at least 18 years
of age, planned to live in the region for at least 1 year and provided
written informed consent (Stein et al., 2015; Zar et al., 2015).
This sub-study and the DCHS were approved by the Faculty of
Health Sciences, Human Research Ethics Committee (HREC) of the
University of Cape Town (HREC 401/2009 and HREC 648/2018).
2.2. Study procedures
2.2.1. Variable measures and collection
Routine HIV testing of pregnant women was conducted to confirm
HIV status in accordance with the Western Cape prevention of mother-
to-child transmission (PMTCT) HIV guidelines (Pellowski et al., 2019).
All HIV-exposed children received HIV testing as per local guidelines,
and all HEU children in the sub-sample were confirmed negative. De-
tection of HIV was done at 6 weeks by PCR and at 9months and
18months by rapid antibody, PCR or ELISA (Zar et al., 2015).
Maternal CD4 cell count and viral load during pregnancy were
measured, with the result closest to 26weeks’ gestation taken to coin-
cide with the immune variables. Viral load was categorized as below
the detectable limit with < 40 copies/ml, detectable with 40–1000
copies/ml and unsuppressed with > 1000 copies/ml. All mothers
living with HIV received antiretroviral therapy (ART) during pregnancy
according to PMTCT guidelines at the time. Maternal ART initiation
was categorized as ‘before pregnancy’ or ‘during pregnancy’. All HEU
infants received prophylaxis (nevirapine alone or combined with zi-
dovudine) from birth (Pellowski et al., 2019).
Blood serum samples were taken at 26 weeks gestation for mothers
and at 6–10weeks and 24–28months for children as outlined in the
DCHS (Zar et al., 2015).
Sociodemographic information was collected using an interviewer
administered questionnaire adapted from items used in the South
African Stress and Health Study. Mothers self-reported employment
status, education level, asset ownership, household income and clinic
during an antenatal study visit between 28- and 32-weeks gestation
(Stein et al., 2015; Zar et al., 2015).
Upon delivery detailed birth data was obtained, including mode of
delivery, gestational age, infant sex, head circumference, infant length
and infant birth weight. Gestational age was calculated using the best
estimated delivery date based on the last menstrual period, antenatal
ultrasound, or the symphysis-fundal height. Prematurity was defined
at< 37weeks gestation (Budree et al., 2017b). Maternal Body Mass
Index (BMI) was determined at 6 weeks postpartum (Budree et al.,
2017b). Self-reported information on child feeding practices was ob-
tained at infant follow-up visits at 6–10 weeks, and 24–28months of
age. At 6–10 weeks infants were categorized as exclusively breastfed if
mothers were still breastfeeding but neither solids nor formula had
been introduced (Budree et al., 2017a; Wedderburn et al., 2019b; Zar
et al., 2015).
Maternal alcohol use during pregnancy was assessed using the
Alcohol, Smoking, and Substance Involvement Screening Test; mothers
were classified with either moderate-severe alcohol exposure vs. un-
exposed (Stein et al., 2015). Infants and children were classified as
being alcohol-exposed in utero if their mother was classified with
moderate-severe alcohol exposure. Smoke exposure was measured at
26 weeks gestation using urine cotinine levels that were determined
using the IMMULITE 1000 nicotine metabolite kit (Vanker et al., 2016).
Mothers were considered a non-smoker if cotinine levels were <
10 ng/ml, a passive smoker with levels between 10 and 500 ng/ml and
an active smoker with levels > 500 ng/ml.
2.2.2. Neurodevelopmental assessment
Neurodevelopment of the children at 24–28months was assessed
with the Bayley Scales of Infant and Toddler Development, third edition
(BSID-III) assessment (Bayley, 2006; Donald et al., 2018). The BSID-III
is a well-validated tool that assesses child cognitive, language and
motor development from 1 to 42months and is sensitive to
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developmental delay (Bayley, 2006). The BSID-III testing was per-
formed by trained assessors that were blinded to maternal HIV status.
Training was performed in accordance with the BSID manual by a pe-
diatric neurodevelopmental specialist who periodically monitored the
assessors throughout the testing period to validate standardized data
collection across sites and ensure agreement between assessors on both
administration and scoring. The assessors alternated between the TC
Newman and Mbekweni clinics and assessed equal number of children
at each site. Assessments were performed with prompts in the child’s
preferred language. External scoring quality control checks were also
performed centrally before data capture. For the current study stan-
dardized composite scores were used. Composite scores were generated
for each cognitive, language and motor domain, with a mean of 100 and
standard deviation of 15, using normative United States data. The use of
these composite scores have been validated in the South African setting
(Ballot et al., 2017; Rademeyer and Jacklin, 2013).
2.2.3. Immune assays
Pro- and anti-inflammatory cytokines have been used as an in-
dicator of immune regulation in the majority of existing studies with
HEU children (Borges-Almeida et al., 2011; Chougnet et al., 2000;
Dirajlal-Fargo et al., 2019; Miyamoto et al., 2017; Prendergast et al.,
2017), pregnant women living with HIV (Faye et al., 2007; Maharaj
et al., 2017; Moussa et al., 2001; Richardson and Weinberg, 2011;
Sachdeva et al., 2008) and brain disorders in children (Miyamoto et al.,
2017). Serum neutrophil gelatinase-associated lipocalin (NGAL) levels
were shown to be associated with cognitive impairments and reduced
brain volumes in people living with HIV (Williams et al., 2019, 2020).
NGAL levels were increased in the neocortex of post-mortem brain
tissues from a subset of people living with HIV that had HIV-associated
neuropathology. NGAL levels correlated with viral load in the CSF and
pro-viral DNA in the cortex (Ojeda-Juárez et al., 2020). The study by
Ojeda-Juárez and colleagues further showed that NGAL may play an
important function in neuronal damage and neuroinflammation in a
HIVgp120 transgenic mouse model for HIV (Ojeda-Juárez et al., 2020).
Decreased plasma MMP-9 levels were found in South African people
living with HIV (Williams et al., 2019). Evidence from studies in ani-
mals show that optimal maternal and infant MMP-9 levels are crucial
for early life brain developmental processes (Reinhard et al., 2015).
NGAL and MMP-9 concentrations were measured using commer-
cially available ELISA kits (NGAL: DY1757, MMP-9: D911; R&D sys-
tems) in serum samples obtained from the mothers at 26 weeks gesta-
tion and the HEU children at 6–10 weeks and 24–28months. Pro- and
anti-inflammatory immune markers (GM-CSF, INF-γ, IL-1β, IL-2, IL-5,
IL-6, IL-7, IL-8 and TNF-α, IL-4, IL-10, IL-12p70 and IL-13) were ana-
lyzed with a Milliplex® Luminex premix 13-plex kit
(HSTCMAG28SPMX13; Merck) according to the manufacturer’s in-
structions. Plates were read on a Luminex system (Bio-Plex 200 System;
Bio-Rad). All samples were assayed in duplicate.
2.3. Statistical analysis
All data were tested for normality. Because of the skewed dis-
tribution, all markers were natural logarithm (ln) transformed. This
resulted in acceptable skewness and kurtosis of the data, which were
used for further statistical analyses. Cytokine levels below the level of
detection (GM-CSF (n= 9), INF-γ (n=2), IL-1β (n= 33), IL-2 (n=5),
IL-5 (n=13), IL-6 (n= 5), IL-4 (n= 5), IL-10 (n=3), IL-12p70
(n=3) and IL-13 (n=17)) were replaced by values representing half
of the lowest value on the standard curve. Variables with missing values
were: smoking status (n=8), alcohol use (n=14), socioeconomic
status (n= 5), BMI at 6 weeks (n= 51), breastfeeding at 6–10 weeks
(n=20), viral load (n=26), CD4+ count (n=19) and finally birth
weight (n= 2). Data was tested for random missingness using Little’s
Missing Completely at Random (MCAR) test that showed a non-sig-
nificant coefficient, χ2=25.48 (df= 29; p=0.653). The data was
therefore considered either MCAR or missing at random (MAR) and
imputed using multiple imputation approach by chained equations
(MICE) to replace the missing values (Rubin and McHugh, 1987). Sta-
tistical analyses were performed on ten imputed datasets. The Benja-
mini-Hochberg procedure was used to control for the false discovery
rate throughout the analyses due to multiple testing (McDonald, 2009).
First, unpaired t-tests were used to explore the differences of the
inflammatory markers in mothers during pregnancy and children at
6–10 weeks and 24–28months according to maternal HIV status.
Significant correlations were subsequently used in linear regression
analyses with the respective markers as dependent variables, maternal
HIV status as predictor and adjusted for covariates. Pearson’s correla-
tions were used to explore the associations between the inflammatory
markers at each time point with neurodevelopment measures at
24–28months of age. Multivariable regression models were then per-
formed separately on significant findings with the respective in-
flammatory markers as predictors and neurodevelopment measure as
dependent variable. Covariates were selected a priori based on their
potential effects on either inflammatory markers or neurodevelopment.
The following variables were added to the model: unadjusted; Model 1)
maternal sociodemographic and lifestyle factors (adjusted for clinic,
maternal smoking during pregnancy, maternal alcohol use during
pregnancy, maternal socioeconomic status, maternal BMI at 6 weeks
postpartum); model 2) infant health (adjusted for birth weight, pre-
maturity, infant sex and exclusive breastfeeding (yes/no)); model 3)
maternal HIV disease parameters (adjusted for maternal CD4+ during
pregnancy, maternal viral load during pregnancy, maternal ART re-
gimen during pregnancy and initiation of ART (before or during preg-
nancy)). All analyses were conducted using SPSS (version 25, IBM,
USA). Group differences were considered statistically significant for all
analyses where p-values were<0.05.
3. Results
3.1. Participants
Table 1 presents demographic data for mothers included in the
study; sociodemographic characteristics were similar across comparison
groups. There were significantly more women living with HIV from
Mbekweni compared to TC Newman clinic (p < 0.001) as well as more
mothers living with HIV with moderate-severe alcohol exposure com-
pared to HIV-uninfected mothers (p = 0.032).
Table 2 presents characteristics of HU and HEU children at
6–10 weeks and at 24–28months. Both HEU and HU groups had similar
growth indices at 6–10weeks and 24–28months. More HU infants were
exclusively breastfed at 6–10 weeks compared to HEU infants
(p = 0.032). However, overall low rates of exclusive breastfeeding at
6–10 weeks occurred (45.5% in HEU and 60.8% in HU group), similar
to findings across the cohort (Budree et al., 2017a). HEU children of this
sub-study did not present with significant impaired neurodevelop-
mental scores compared to HU children.
3.2. Inflammatory markers according to maternal HIV status
Serum levels of the inflammatory markers GM-CSF (p = 0.003)
(Fig. 1A) and MMP-9 (p < 0.001) (Fig. 1B) were significantly lower in
mothers living with HIV compared to HIV-uninfected mothers at
26 weeks gestation. The inflammatory markers IL-1β (p = 0.021) and
IL-4 (p = 0.019) were also lower in mothers living with HIV (p < 0.05
uncorrected), however this was not significant after multiple comparison
correction.
In infants at 6–10 weeks serum levels of the inflammatory markers
IFN-γ (p = 0.006) (Fig. 1C) and IL-1β (p = 0.006) (Fig. 1D) were de-
creased in HEU compared to HU infants. The inflammatory markers IL-
12p70 and IL-4 were lower in HEU infants (p < 0.05 uncorrected) but
this was not significant after multiple comparison correction.
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In children at 24–28months serum levels of inflammatory markers
IFN-γ (p = 0.005) (Fig. 1E), IL-1β (p < 0.001) (Fig. 1F), IL-2
(p = 0.004) (Fig. 1G) and IL-4 (p = 0.013) (Fig. 1H) were all sig-
nificantly lower in HEU compared with HU children after multiple
comparison correction.
Fig. 1 indicates all inflammatory markers that were significantly
reduced in mothers living with HIV and their HEU children compared
to HIV-uninfected mothers and their HU children. The natural log (ln)
transformed values for all the inflammatory markers for the mothers
living with HIV and HIV-uninfected mothers and their children are
shown in the supplementary file (supplementary Tables 1-3).
Multivariable linear regression analyses were performed for in-
flammatory markers according to maternal HIV status (Table 3). In
adjusted analyses, GM-CSF (p = 0.016) and MMP-9 (p = 0.034) was
significantly lower in mothers living with HIV. At 6–10weeks, IFN-γ
(p = 0.001) was significantly lower in HEU compared to HU infants; IL-
1β (p = 0.120) was not significant after controlling for all covariates.
By 24–28months, IFN-γ (p = 0.019) IL-1β (p = 0.001), IL-2
(p = 0.035) and IL-4 (p = 0.017) levels were significantly lower in HEU
children after controlling for covariates.
3.3. Association of inflammatory markers with neurodevelopment
No inflammatory markers in mothers living with HIV were sig-
nificantly associated with neurodevelopmental measures in HEU chil-
dren after correction for multiple comparisons. However, markers of
inflammation in mothers living with HIV [IFN-γ (r = -0.295, p = 0.01),
IL-10 (r = -0.253, p = 0.036), IL-12p70 (r = -0.262, p = 0.030) and IL-
7 (r = -0.246, p = 0.041)] were associated with lower composite scores
for language in HEU children (24–28months) on initial analysis; but
were not significant after multiple comparison correction. TNF-α (r = -
0.288, p = 0.014) was also associated initially with lower cognitive
scores in HEU children (24–28months) prior to multiple comparison
correction (Table 4).
In HEU infants (6–10weeks) most inflammatory markers [GM-CSF
(r = 10.309, p0.022), IFN-γ (r = -0.339, p = 0.011), IL-10 (r = -0.451,
p = 0.001), IL-12p70 (r = -0.379, p = 0.004), IL-1β (r = -0.491,
p < 0.000), IL-2 (r = -0.308, p = 0.022), IL-4 (r = -0.418, p = 0.002),
IL-6 and NGAL (r = -0.383, p = 0.004)] were significantly associated
with motor development in HEU children (24–28months) after cor-
rection for multiple comparisons. MMP-9 was shown to be initially
associated with motor (r = -0.289, p = 0.034) and language outcomes
Table 1
Descriptive demographic characteristics for HIV-infected and HIV-uninfected mothers and neonatal measures at birth.
MOTHERS HIV-infected HIV-uninfected P-value
N (%) 77 (28.8) 190 (71.2)
Age, mean (SD) 29 (5.43) 26 (5.87) 0.377
Site, N (%) <0.001
Mbekweni 70/77 (90.9) 70/190 (36.8)
TC Newman 7/77 (9.1) 120/190 (63.2)
Education, N (%) 0.289
Primary 8/77 (10.4) 14/190 (7.4)
Some secondary 50/77 (64.9) 108/190 (56.8)
Secondary 17/77 (22.1) 56/190 (29.5)
Tertiary 2/77 (2.6) 12/190 (6.3)
Married, N (%) 0.933
Married/cohabitating 29/77 (37.7) 75/190 (39.5)
Other 48/77 (62.3) 115/190 (60.5)
Body Mass Index (BMI), mean (SD) 28.81 (6.60) 26.23 (6.06) 0.551
Smoking (urine cotinine levels ng/ml), N (%) 0.235
Non-smoker (< 10 ng/ml) 21/74 (28.4) 37/185 (20.0)
Passive smoker (10–500 ng/ml) 31/74 (41.9) 76/185 (41.1)
Active smoker (> 500 ng/ml) 22/74 (29.7) 72/185 (38.5)
Alcohol exposure, N (%) 0.032
Unexposed 61/68 (89.7) 179/185 (96.8)
Moderate-severe exposure 7/68 (10.3) 6/185 (3.2)
Illness during pregnancy, N (%) 11/77 (14.2) 17/190 (8.9) 0.213
Maternal CD4+ count in pregnancy, median (range) 453.50 (339.25–628.00) – –
Viral load during pregnancy, N (%)
Below detectable limit (< 40 copies/mL) 40/51 (78.4) – –
Detectable (≥40-1000 copies/mL) 5/51 (9.8) – –
Unsuppressed (> 1000 copies/mL) 6/51 (11.8) – –
Antiretroviral regimen during pregnancy, N (%)
Prevention of mother-to-child transmission
prophylaxis (zidovudine) 11/77 (14.3) – –
First-line triple therapy 64/77 (83.1) – –
Second-line or third-line therapy 2/77 (2.60) – –
Initiation of antiretroviral treatment, N (%)
Before pregnancy 32/77 (41.6) – –
During pregnancy 45/77 (58.4) – –
Social-economic status (SES), N (%) 0.475
Lowest SES 25/77 (32.5) 43/185 (23.2)
Low-moderate SES 17/77 (22.1) 49/185 (26.5)
Moderate-high SES 20/77 (26.0) 55/185 (29.7)
High SES 15/77 (19.5) 38/185 (20.5)
Prematurity (< 37weeks), N (%) 8/77 (10.4) 26/188 (13.8) 0.464
Birth weight, mean (SD) 3.02 (0.52) 3.02 (0.59) 0.202
Delivery Method, N (%) 0.052
Vaginal 48/77 (69.6) 151/181 (83.4)
Elective Cesarean 6/77 (8.7) 9/181 (5.0)
Emergency Cesarean 15/77 (21.7) 21/181 (11.6)
SD: standard deviation, N: numbers.
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(r = -0.305, p = 0.022) prior to multiple comparison correction.
Additionally, IL-1β (r = -0.342, p = 0.008) was associated with lan-
guage outcomes prior to multiple comparison correction (Table 4).
No associations of inflammatory markers in HEU children
(24–28months) with neurodevelopment measures reached statistical
significance after correction for multiple comparisons. However, in
HEU children (24–28months) IL-10 (r = -0.303, p = 0.010) was asso-
ciated with lower cognitive scores prior to multiple comparison cor-
rection. Inflammatory markers IFN-γ (r = -0.307, p = 0.011), IL-10
(r = -0.319, p = 0.008), IL-12p70 (r = -0.284, p = 0.019), IL-1β (r = -
0.241, p = 0.048) and IL-2 (r = -0.253, p = 0.037) were also associated
with language outcomes prior to multiple comparison correction
(Table 4).
There were no significant correlations between inflammatory mar-
kers in the HIV-uninfected mothers and their HU children with neuro-
developmental measures after multiple comparison corrections (sup-
plementary Tables 4-6).
Multivariable linear regression analyses on inflammatory markers of
HEU infants at 6–10weeks with motor development at 24–28months
showed that GM-CSF, IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-6 and
NGAL were associated with poorer motor development after controlling
for covariates on all three models (p < 0.05) (Table 5).
4. Discussion
This is the first study reporting longitudinal associations between
inflammatory markers in pregnant mothers living with HIV and unin-
fected pregnant mothers and their children with neurodevelopmental
measures. Key findings were that maternal HIV infection was associated
with decreased levels of inflammatory markers in pregnant women and
in their children at 6–10 weeks and 24–28months; there was a sig-
nificant association between inflammatory markers in HEU infants at
6–10 weeks and poorer motor development at 24–28months.
The results of this study are consistent with evidence indicating
inflammatory cytokines that play an important role in immune reg-
ulation during pregnancy may be dysregulated in women living with
HIV. Reduced serum levels of inflammatory cytokines in mothers living
with HIV and HEU children were found, which were consistent with a
few other studies. These studies found reduced levels of IL-2, IL-6 and
TNF-α in mothers living with HIV and reduced levels of IL-4, IL-7 and
IL-12 in HEU infants (Borges-Almeida et al., 2011; Chougnet et al.,
2000; Maharaj et al., 2017). However, the current study differs from
most previously reported studies, which found increased levels of in-
flammatory markers (predominantly IL-1β, IL-6 and TNF-α) in both
mothers living with HIV and HEU children (Dirajlal-Fargo et al., 2019;
Miyamoto et al., 2017; Richardson and Weinberg, 2011). The above
studies were performed mostly in South America, America and Eur-
opean countries, which represent a population of women primarily
infected with the HIV subtype Clade B; only two studies were in sub-
Saharan Africa. The sub-Saharan epidemic of HIV infection, re-
presenting the greatest proportion of people living with HIV and HEU
children worldwide, is largely infected with the HIV subtype Clade C
(Geretti, 2006). Clade C tends to present a more immunosuppressive
profile, in keeping with our findings, compared to other clades such as
Clade B, which have a pro-inflammatory effect with increased neu-
roinflammation possibly due to the amino-acid sequence differences of
the Tat protein (Rao et al., 2013; Ruiz et al., 2019). Our finding of
reduced serum levels of inflammatory markers associated with HIV
infection in pregnant mothers and HEU children, highlights the po-
tential dysregulatory impact of maternal HIV infection on immune
function, particularly during the early critical period of child neuro-
development. The impact of ART on levels of inflammatory markers in
mothers living with HIV and HEU children should also be considered, as
this may reduce systemic inflammation and immune activation to some
extent (Hileman and Funderburg, 2017). The impact of specific ART on
neurodevelopmental outcomes in HEU children should also be taken
into account. A study by Cassidy and colleagues in Botswana showed
that exposure to efavirenz-based ART was associated with lower re-
ceptive language scores at 2 years of age as compared with HEU chil-
dren with non-efavirenz-based ART (Cassidy et al., 2019). Other stu-
dies, however, have found no impact of in utero exposure to specific
ART regimens on neurodevelopmental outcomes in HEU children at
24months of age (Chaudhury et al., 2018; Kacanek et al., 2018) . No-
tably, in our analysis, ART was included as a covariate, and the in-
flammatory environment of the HEU children was consistently low until
2 years of age when the children were no longer exposed to ART di-
rectly. Therefore, a significant impact of ART on cytokine levels and
neurodevelopmental outcomes in HEU children in this cohort appears
less likely, although future research is needed to explore this area.
The reduction in cytokine serum levels in HEU children through the
two years mirrors the reduced levels of cytokines found in their mo-
thers, demonstrating a persistent effect. This suggests that the mothers’
immune profile may predict that of their children. Many studies have
found that the maternal immune system significantly impacts the im-
mune system of the fetus (Morelli et al., 2015). One potential me-
chanism is through the transfer of maternal cytokines across the pla-
centa (Abu-Raya et al., 2016b; Morelli et al., 2015). Notably, the
mothers living with HIV in this study had lower GM-CSF levels. GM-CSF
is a cytokine that plays an important function in the survival and ac-
tivation of mature myeloid cells and contributes to the maintenance of
the innate immune system (Hamilton and Achuthan, 2013). Studies
with GM-CSF or Csf2rb (receptor for GM-CSF) knockout mice had a
reduction of conventional dendritic cells (cDC), with a most pro-
nounced decrease in the cDC1 lineage (Bogunovic et al., 2009; Greter
et al., 2012; Kingston et al., 2009). In GM-CSF deficient mice it was also
found that GM-CSF is important for Th type 1 (Th1) and Th2 responses
to antigenic stimulation (Wada et al., 1997). These studies indicate that
insufficient GM-CSF levels lead to an impaired development of the
immune system and reduced immune response. We speculate that the
lower GM-CSF levels during pregnancy in women living with HIV can
contribute to an altered immune development in the HEU children,
which is reflected by persistent decreased pro-inflammatory (IFN-γ and
IL-1β) and anti-inflammatory cytokine (IL-4) levels in the children at
6–10 weeks and 24months of age. There are very few studies that assess
the inflammatory profile of HEU children longitudinally, highlighting
the importance of this study and need for future investigation in this
area.
Table 2
Descriptive characteristics for HEU and HU children at 6–10weeks and
24–28months.
INFANTS 6 WEEKS HEU HU P-value
N (%) 63 (71.6) 159 (28.4)
Age (weeks), mean (SD) 8.1 (1.5) 7.9 (1.6) 0.277
Baby sex (Female) N (%) 37 (59.7) 89 (57.1) 0.723
Weight (Kg), mean (SD) 4.91 (0.70) 4.83 (0.79) 0.505
Length (cm), mean (SD) 54.75 (2.66) 54.67 (2.90) 0.370
Head circumference (cm), mean (SD) 38.86 (1.54) 38.61 (1.81) 0.197
Exclusive breast feeding, N (%) 30 (45.5) 110 (60.8) 0.032
Cotrimoxazole use, N (%) 50 (80.6) – –
CHILDREN 24 MONTHS
N (%) 77 (28.8) 190 (71.2)
Age (months), mean (SD) 27.3 (4.0) 27.2 (3.5) 0.331
Baby sex (Female) N (%) 47 (61.0) 113 (59.5) 0.813
Weight (Kg), mean (SD) 11.98 (1.88) 11.61 (1.63) 0.249
Length (cm), mean (SD) 83.40 (3.65) 83.73 (3.54) 0.889
Head circumference (cm), mean (SD) 48.43 (2.15) 47.96 (1.89) 0.858
Cognitive, mean (SD) 85.62 (8.68) 86.64 (9.05) 0.641
Language, mean (SD) 82.42 (10.26) 85.20 (12.55) 0.118
Motor, mean (SD) 94.38 (11.83) 94.57 (13.52) 0.854
Abbreviations: HEU, HIV-exposed uninfected; HU, HIV-unexposed; SD,
Standard deviation; N, numbers; Kg, Kilograms; cm, centimeters.
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Our results demonstrated that increased levels of several immune
markers (GM-CSF, IFN-γ, IL-10, IL12p70, IL-1β, IL-2, IL-4, IL-6 and
NGAL) in HEU infants at 6–10 weeks were associated with poorer motor
development at 2 years. This suggests that an altered immune system
early in life may predict neurodevelopmental delay in later childhood.
A review by Bilbo et al supports this by highlighting the impact of the
immune system on normal brain development (Bilbo and Schwarz,
2012). HEU infants may have a more sensitive immune system com-
pared to HU infants and consequently this may result in increased
susceptibility to changes in levels of inflammatory markers. HEU in-
fants may manifest a lower threshold for the impact of fluctuations in
inflammatory markers on the developing brain. This theory is
Fig. 1. Comparisons of serum levels of all inflammatory markers that were significantly different in mothers living with HIV and their HEU children compared to HIV
uninfected mothers and HU children.
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supported by evidence that HIV exposure impacts the immune system
of HEU children (Abu-Raya et al., 2016a). On the other hand, the im-
mune systems of unexposed infants are assumed to be functioning
under typical physiological conditions and therefore may be able to
adapt more easily to fluctuations in inflammatory markers. Previous
findings in animal models suggest that maternal immune compromise
also affects neurodevelopment via changes in fetal inflammatory
markers (Yockey and Iwasaki, 2018).
Poorer language functioning in HEU children was associated with
increased serum levels of IFN-γ, IL-10 and IL-12p70 in mothers living
with HIV and their children before multiple comparison correction.
This finding, though not reaching statistical significance remains im-
portant to note, as studies reporting on associations between HEU and
early development have consistently found that early language out-
comes are affected (Le Doare et al., 2012). We recently reported that
HEU children in the DCHS (Wedderburn et al., 2019b) showed sig-
nificantly lower language scores compared with HU children at 2 years
of age. Further investigation into the impact of HIV exposure and me-
chanisms for impact on language neurodevelopment is needed.
Limitations of this study include the modest sample size warranting
replication in a larger study; however, this is one of the largest studies
to investigate inflammatory markers longitudinally in HEU and HU
children. Although the study population is characteristic of this region
of South Africa and many other parts of sub-Saharan Africa, care must
be taken when extrapolating the results to other environments. The
findings may not apply to populations with HIV clades other than HIV
clade-C, which is the predominant clade in sub-Saharan Africa, as HIV
subtypes may affect immune markers (Gandhi et al., 2009).
5. Conclusion
This follow-up study demonstrates that maternal HIV infection is
associated with immune dysregulation with results indicating sup-
pressed levels of serum inflammatory markers in mothers living with
HIV and HEU children through to two years of age. The results further
show that an altered immune system in HEU infants is associated with
poorer motor development in children at two years. This study adds to
the emerging understanding of the role of HIV and the immune system
in neurodevelopment. Further, the findings suggest potential mechan-
isms through which early interventions may be developed in order to
support optimal neurodevelopmental outcomes in HEU children across
their lifespan.
Table 3
Multivariable linear regression analyses of inflammatory markers in mothers,
infants (6–10 weeks) and children (24–28months).
B (SE) β P-value
Mothers*
GM-CSF −0.060 (0.03) −0.122 0.016
MMP-9 −0.076 (0.04) −0.124 0.034
Infants 6–10weeks#
IFN-γ −0.088 (0.03) −0.194 0.001
IL-1β −0.048 (0.03) −0.098 0.120
Children 24–28months†
IFN-γ −0.097 (0.04) −0.168 0.019
IL-1β −0.110 (0.03) −0.182 0.001
IL-2 −0.075 (0.04) −0.116 0.035
IL-4 −0.060 (0.03) −0.128 0.017
Multivariable regressions were performed separately for each inflammatory
marker with significant differences after correcting for multiple comparisons,
according to maternal HIV status as depicted in Fig. 1.
Abbreviations: GM-CSF, Granulocyte-macrophage colony-stimulating factor;
MMP-9 metalloproteinase-9; IFN-γ, interferon-γ; IL, interleukin
* covariates: clinic, smoking, alcohol exposure, age, socioeconomic status
and body mass index (BMI) at 6 weeks postpartum.
# covariates: clinic, maternal smoking during pregnancy maternal alcohol
exposure during pregnancy, maternal socioeconomic status and maternal BMI
at 6 weeks postpartum, prematurity, birth weight, exclusive breastfeeding at
6–10weeks and infant sex.
† covariates: clinic, maternal smoking during pregnancy, maternal alcohol
exposure during pregnancy, prematurity, maternal socioeconomic status and
maternal BMI at 6 weeks postpartum, birth weight and child sex.
Table 4
Correlation between inflammatory markers in mothers living with HIV and HEU children at 6–10weeks and 24–28months with neurodevelopment outcomes at
24–28months.
HIV-infected Mothers
GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α NGAL MMP9
Cognitive r 0.085 -0.131 -0.069 -0.045 -0.051 -0.023 -0.086 0.049 -0.128 -0.144 -0.226 -0.071 -0.288 -0.016 -0.122
P-value 0.477 0.272 0.566 0.705 0.669 0.850 0.475 0.684 0.283 0.227 0.057 0.556 0.014 0.892 0.307
Language r -0.142 -0.295 -0.253 -0.262 -0.174 -0.223 -0.232 -0.208 -0.211 -0.204 -0.246 -0.128 -0.206 0.081 0.045
P-value 0.245 0.014 0.036 0.030 0.153 0.066 0.056 0.086 0.081 0.093 0.041 0.295 0.089 0.509 0.711
Motor r 0.031 -0.166 -0.147 -0.164 -0.082 -0.133 -0.085 -0.123 -0.134 0.012 -0.109 -0.029 -0.138 -0.036 -0.068
P-value 0.807 0.182 0.240 0.189 0.511 0.288 0.496 0.325 0.283 0.923 0.383 0.815 0.269 0.775 0.589
HEU Infants (6–10weeks)
GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α NGAL MMP9
Cognitive r 0.005 -0.178 -0.136 -0.089 -0.091 -0.207 -0.126 -0.164 -0.010 -0.181 -0.238 -0.225 -0.178 -0.153 -0.186
P-value 0.971 0.178 0.305 0.501 0.492 0.116 0.343 0.214 0.938 0.171 0.070 0.086 0.177 0.251 0.162
Language r 0.081 -0.106 -0.116 -0.055 -0.025 -0.199 0.007 -0.182 -0.070 -0.165 -0.061 -0.221 -0.152 -0.169 -0.305
P-value 0.548 0.430 0.390 0.684 0.855 0.138 0.958 0.177 0.607 0.220 0.654 0.098 0.260 0.214 0.022
Motor r -0.309# -0.339# -0.451# -0.379# -0.243 -0.491# -0.308# -0.418# -0.237 -0.335# -0.239 -0.003 -0.071 -0.383# -0.289
p-value 0.022 0.011 0.001 0.004 0.074 0.000 0.022 0.002 0.082 0.012 0.079 0.981 0.607 0.004 0.034
HEU Children (24–28months)
GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α NGAL MMP9
Cognitive r -0.032 -0.191 -0.303 -0.166 0.018 -0.148 -0.148 -0.118 0.013 -0.106 -0.177 0.010 -0.054 0.207 -0.007
P-value 0.793 0.111 0.010 0.166 0.884 0.217 0.219 0.329 0.916 0.381 0.139 0.933 0.654 0.081 0.956
Language r -0.234 -0.307 -0.319 -0.284 0.029 -0.241 -0.253 -0.217 -0.049 -0.012 -0.140 -0.025 -0.083 0.159 -0.001
P-value 0.055 0.011 0.008 0.019 0.817 0.048 0.037 0.076 0.690 0.922 0.255 0.842 0.503 0.193 0.991
Motor r -0.050 -0.073 -0.215 -0.143 0.089 -0.124 -0.011 -0.154 0.100 0.091 -0.028 0.105 -0.027 0.112 0.023
P-value 0.690 0.562 0.086 0.256 0.480 0.326 0.934 0.221 0.429 0.473 0.825 0.405 0.830 0.371 0.856
# Remained significant after correcting for multiple comparisons.
Abbreviations: GM-CSF, Granulocyte-macrophage colony-stimulating factor; MMP-9 metalloproteinase-9; IFN-γ, interferon-γ; IL, interleukin; NGAL, neutrophil
gelatinase-associated lipocalin; TNF-α, Tumor-necrosis factor-α; HIV, Human Immunodeficiency Virus; HEU, HIV-exposed uninfected.
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